Patents by Inventor Monique Lafon
Monique Lafon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11339211Abstract: The invention is in the domain of delivery of molecules to brain cells across the blood-brain barrier. The invention relates to a novel polypeptide-based carrier that allows the efficient delivery of an effector peptide, to neuron cells across the blood-brain barrier, and to methods for the production and testing of such carrier, including a model for testing the capacity of such molecule to cross the blood-brain barrier and/or the toxicity of molecules on the blood brain barrier and/or the capacity of molecules that have crossed to target human brain cells (e/g. neurons, astrocytes and microglial cells).Type: GrantFiled: April 2, 2020Date of Patent: May 24, 2022Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Christophe Prehaud, Monique Lafon, Pierre Lafaye
-
Publication number: 20210040187Abstract: The invention is in the domain of delivery of molecules to brain cells across the blood-brain barrier. The invention relates to a novel polypeptide-based carrier that allows the efficient delivery of an effector peptide, to neuron cells across the blood-brain barrier, and to methods for the production and testing of such carrier, including a model for testing the capacity of such molecule to cross the blood-brain barrier and/or the toxicity of molecules on the blood brain barrier and/or the capacity of molecules that have crossed to target human brain cells (e/g. neurons, astrocytes and microglial cells).Type: ApplicationFiled: April 2, 2020Publication date: February 11, 2021Inventors: Christophe PREHAUD, Monique LAFON, Pierre LAFAYE
-
Patent number: 10640552Abstract: The invention is in the domain of delivery of molecules to brain cells across the blood-brain barrier. The invention relates to a novel polypeptide-based carrier that allows the efficient delivery of an effector peptide, to neuron cells across the blood-brain barrier, and to methods for the production and testing of such carrier, including a model for testing the capacity of such molecule to cross the blood-brain barrier and/or the toxicity of molecules on the blood brain barrier and/or the capacity of molecules that have crossed to target human brain cells (e.g. neurons, astrocytes and microglial cells).Type: GrantFiled: September 9, 2015Date of Patent: May 5, 2020Assignees: Institut Pasteur, Centre National de la Recherche ScientifiqueInventors: Christophe Prehaud, Monique Lafon, Pierre Lafaye
-
Patent number: 10591466Abstract: The invention is in the domain of delivery of molecules to brain cells across the blood-brain barrier. The invention relates to a novel polypeptide-based carrier that allows the efficient delivery of an effector peptide, to neuron cells across the blood-brain barrier, and to methods for the production and testing of such carrier, including a model for testing the capacity of such molecule to cross the blood-brain barrier and/or the toxicity of molecules on the blood brain barrier and/or the capacity of molecules that have crossed to target human brain cells (e/g. neurons, astrocytes and microglial cells).Type: GrantFiled: September 9, 2015Date of Patent: March 17, 2020Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALEInventors: Christophe Prehaud, Monique Lafon, Pierre-Emmanuel Ceccaldi, Philippe Afonso, Pierre Lafaye
-
Patent number: 10227653Abstract: The invention relates to polypeptides containing a cytoplasmic domain ending with a MAST-2 binding domain, from 11 to 13 residues, the first two residues of which are S and W, and the last four residues of which are Q, T, R and L, the polypeptides presenting a high affinity for the PDZ domain of the human MAST2 protein. The invention also relates to polynucleotides, vectors, lentiviral particles, cells as well as compositions containing the same. The invention is also directed to the use of the polypeptides, polynucleotides, vectors, lentiviral particles, cells and compositions in the treatment and/or prevention of a disease, disorder or condition, which alters the Central Nervous System (CNS) and/or the Peripheral Nervous System (PNS). The invention also concerns molecular signatures of cellular genes to determine the neurosurvival and/or neuroprotection activity of a molecule.Type: GrantFiled: September 14, 2016Date of Patent: March 12, 2019Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6)Inventors: Christophe Prehaud, Monique Lafon, Nicolas Wolff, Zakir Khan, Elouan Terrien, Sandrine Vitry
-
Publication number: 20170283490Abstract: The invention is in the domain of delivery of molecules to brain cells across the blood-brain barrier. The invention relates to a novel polypeptide-based carrier that allows the efficient delivery of an effector peptide, to neuron cells across the blood-brain barrier, and to methods for the production and testing of such carrier, including a model for testing the capacity of such molecule to cross the blood-brain barrier and/or the toxicity of molecules on the blood brain barrier and/or the capacity of molecules that have crossed to target human brain cells (e/g. neurons, astrocytes and microglial cells).Type: ApplicationFiled: September 9, 2015Publication date: October 5, 2017Inventors: Christophe PREHAUD, Monique LAFON, Pierre LAFAYE
-
Publication number: 20170241988Abstract: The invention is in the domain of delivery of molecules to brain cells across the blood-brain barrier. The invention relates to a novel polypeptide-based carrier that allows the efficient delivery of an effector peptide, to neuron cells across the blood-brain barrier, and to methods for the production and testing of such carrier, including a model for testing the capacity of such molecule to cross the blood-brain barrier and/or the toxicity of molecules on the blood brain barrier and/or the capacity of molecules that have crossed to target human brain cells (e/g. neurons, astrocytes and microglial cells).Type: ApplicationFiled: September 9, 2015Publication date: August 24, 2017Inventors: Christophe PREHAUD, Monique LAFON, Pierre-Emmanuel CECCALDI, Philippe AFONSO, Pierre LAFAYE
-
Publication number: 20170022567Abstract: The invention relates to polypeptides containing a cytoplasmic domain ending with a MAST-2 binding domain, from 11 to 13 residues, the first two residues of which are S and W, and the last four residues of which are Q, T, R and L, the polypeptides presenting a high affinity for the PDZ domain of the human MAST2 protein. The invention also relates to polynucleotides, vectors, lentiviral particles, cells as well as compositions containing the same. The invention is also directed to the use of the polypeptides, polynucleotides, vectors, lentiviral particles, cells and compositions in the treatment and/or prevention of a disease, disorder or condition, which alters the Central Nervous System (CNS) and/or the Peripheral Nervous System (PNS). The invention also concerns molecular signatures of cellular genes to determine the neurosurvival and/or neuroprotection activity of a molecule.Type: ApplicationFiled: September 14, 2016Publication date: January 26, 2017Inventors: Christophe Prehaud, Monique Lafon, Nicolas Wolff, Zakir Khan, Elouan Terrien, Sandrine Vitry
-
Patent number: 9475851Abstract: The invention relates to polypeptides containing a cytoplasmic domain ending with a MAST-2 binding domain, from 11 to 13 residues, the first two residues of which are S and W, and the last four residues of which are Q, T, R and L, the polypeptides presenting a high affinity for the PDZ domain of the human MAST2 protein. The invention also relates to polynucleotides, vectors, lentiviral particles, cells as well as compositions containing the same. The invention is also directed to the use of the polypeptides, polynucleotides, vectors, lentiviral particles, cells and compositions in the treatment and/or prevention of a disease, disorder or condition, which alters the Central Nervous System (CNS) and/or the Peripheral Nervous System (PNS). The invention also concerns molecular signatures of cellular genes to determine the neurosurvival and/or neuroprotection activity of a molecule.Type: GrantFiled: November 7, 2012Date of Patent: October 25, 2016Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PIERRE ET MARIE CURIEInventors: Christophe Prehaud, Monique Lafon, Nicolas Wolff, Zakir Khan, Elouan Terrien, Sandrine Vitry
-
Patent number: 9249194Abstract: The invention demonstrates that, contrary to apoptotic rabies virus G proteins, certain non-apoptotic rabies virus G proteins, such as the G protein of the CVS-NIV strain, have a neurite outgrowth promoting effect. The invention further demonstrates that this neurite outgrowth promoting effect is due to the cytoplasmic tail of the non-apoptotic rabies virus G proteins, more particularly to their PDZ-BS, which shows a single-point mutation compared to the one of apoptotic rabies virus G proteins. The invention provides methods for inducing and/or stimulating neurite outgrowth, which are useful in inducing neuron differentiation, for example for the treatment of a neoplasm of the nervous system, as well as in regenerating impaired neurons, for example for the treatment of a neurodegenerative disease, disorder or condition or in the treatment of a microbial infection, or in protecting neurons from neurotoxic agents or oxidative stress.Type: GrantFiled: June 23, 2014Date of Patent: February 2, 2016Assignees: INSTITUT PASTEUR, THOMAS JEFFERSON UNIVERSITYInventors: Christophe Prehaud, Monique Lafon, Matthias Johannes Schnell
-
Patent number: 9234005Abstract: The application provides products, which may trigger pro-apoptotic or pro-death effects on neoplastic cells and/or tissues of the human nervous system, more particularly on neoplastic cells and/or tissues of the human CNS. The products of the application can be used as anti-proliferative or tumoricid agents in the treatment and/or palliation and/or prevention of neoplasms of the human nervous system, more particularly of glioblastoma or brain stem glioma. Therefore, the application also relates to compositions, such as pharmaceutical compositions or drugs, which comprise at least one of said products, as well as to the biotechnological and medical applications of said products and compositions.Type: GrantFiled: October 11, 2012Date of Patent: January 12, 2016Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PIERRE ET MARIE CURIE PARISInventors: Nicolas Wolff, Monique Lafon, Nicolas Babault
-
Publication number: 20140341858Abstract: The invention demonstrates that, contrary to apoptotic rabies virus G proteins, certain non-apoptotic rabies virus G proteins, such as the G protein of the CVS-NIV strain, have a neurite outgrowth promoting effect. The invention further demonstrates that this neurite outgrowth promoting effect is due to the cytoplasmic tail of said non-apoptotic rabies virus G proteins, more particularly to their PDZ-BS, which shows a single-point mutation compared to the one of apoptotic rabies virus G proteins. The invention provides means for inducing and/or stimulating neurite outgrowth, which are useful in inducing neuron differentiation, for example for the treatment of a neoplasm of the nervous system, as well as in regenerating impaired neurons, for example for the treatment of a neurodegenerative disease, disorder or condition or in the treatment of a microbial infection, or in protecting neurons from neurotoxic agents or oxidative stress.Type: ApplicationFiled: June 23, 2014Publication date: November 20, 2014Inventors: Christophe PREHAUD, Monique LAFON, Matthias Johannes SCHNELL
-
Publication number: 20140315822Abstract: The invention relates to polypeptides containing a cytoplasmic domain ending with a MAST-2 binding domain, from 11 to 13 residues, the first two residues of which are S and W, and the last four residues of which are Q, T, R and L, said polypeptides presenting a high affinity for the PDZ domain of the human MAST2 protein. The invention also relates to polynucleotides, vectors, lentiviral particles, cells as well as compositions comprising the same. The invention is also directed to the use of said polypeptides, polynucleotides, vectors, lentiviral particles, cells and compositions in the treatment and/or prevention of a disease, disorder or condition, which alters the Central Nervous System (CNS) and/or the Peripheral Nervous System (PNS). The invention also concerns molecular signatures of cellular genes to determine the neurosurvival and/or neuroprotection activity of a molecule.Type: ApplicationFiled: November 7, 2012Publication date: October 23, 2014Applicant: CENTRE NATIONAL DE LA RECHERCE SCIENTIFIQUEInventors: Christophe Prehaud, Monique Lafon, Nicolas Wolff, Zakir Khan, Elouan Terrien, Sandrine Vitry
-
Publication number: 20140302123Abstract: The application provides products, which may trigger pro-apoptotic or pro-death effects on neoplastic cells and/or tissues of the human nervous system, more particularly on neoplastic cells and/or tissues of the human CNS. The products of the application can be used as anti-proliferative or tumoricid agents in the treatment and/or palliation and/or prevention of neoplasms of the human nervous system, more particularly of glioblastoma or brain stem glioma. Therefore, the application also relates to compositions, such as pharmaceutical compositions or drugs, which comprise at least one of said products, as well as to the biotechnological and medical applications of said products and compositions.Type: ApplicationFiled: October 11, 2012Publication date: October 9, 2014Inventors: Nicolas Wolfe, Monique Lafon, Nicolas Babault
-
Patent number: 8822665Abstract: The invention demonstrates that, contrary to apoptotic rabies virus G proteins, certain non-apoptotic rabies virus G proteins, such as the G protein of the CVS-NIV strain, have a neurite outgrowth promoting effect. The invention further demonstrates that this neurite outgrowth promoting effect is due to the cytoplasmic tail of said non-apoptotic rabies virus G proteins, more particularly to their PDZ-BS, which shows a single-point mutation compared to the one of apoptotic rabies virus G proteins. The invention provides means for inducing and/or stimulating neurite outgrowth, which are useful in inducing neuron differentiation, for example for the treatment of a neoplasm of the nervous system, as well as in regenerating impaired neurons, for example for the treatment of a neurodegenerative disease, disorder or condition or in the treatment of a microbial infection, or in protecting neurons from neurotoxic agents or oxidative stress.Type: GrantFiled: April 2, 2010Date of Patent: September 2, 2014Assignees: Institut Pasteur, Thomas Jefferson UniversityInventors: Christophe Prehaud, Monique Lafon, Matthias Johannes Schnell
-
Publication number: 20120100116Abstract: The invention demonstrates that, contrary to apoptotic rabies virus G proteins, certain non-apoptotic rabies virus G proteins, such as the G protein of the CVS-NIV strain, have a neurite outgrowth promoting effect. The invention further demonstrates that this neurite outgrowth promoting effect is due to the cytoplasmic tail of said non-apoptotic rabies virus G proteins, more particularly to their PDZ-BS, which shows a single-point mutation compared to the one of apoptotic rabies virus G proteins. The invention provides means for inducing and/or stimulating neurite outgrowth, which are useful in inducing neuron differentiation, for example for the treatment of a neoplasm of the nervous system, as well as in regenerating impaired neurons, for example for the treatment of a neurodegenerative disease, disorder or condition or in the treatment of a microbial infection, or in protecting neurons from neurotoxic agents or oxidative stress.Type: ApplicationFiled: April 2, 2010Publication date: April 26, 2012Applicants: THOMAS JEFFERSON UNIVERSITY, INSTITUT PASTEURInventors: Christophe Prehaud, Monique Lafon, Matthias Johannes Schnell
-
Publication number: 20060088820Abstract: Multiple sclerosis or a condition associated with multiple sclerosis is detected by detecting an amount of lymphocytes bearing a V?16, V?17 or V?7 determinant and calculating an amount of expansion or loss of these lymphocytes.Type: ApplicationFiled: October 31, 2005Publication date: April 27, 2006Applicant: BIOMERIEUXInventors: Herve Perron, Monique Lafon